Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
<< anterior 21 a 40 de 743 siguiente >>
Presentar resultados
Seleccionar todas
22. Cita con resumen
Johansen ME, Richardson C. Estimation of potential savings through therapeutic substitution. JAMA Intern Med 2016;176:769-75. [Ref.ID 100398]
23. Cita con resumen
Garattini S. The European Medicines Agency is still too close to industry. BMJ 2016;353:i2412. [Ref.ID 100360]
24. Cita con resumen
Alpern JD, Song J, Stauffer WM. Essential medicines in the United States - Why access is diminishing. N Engl J Med 2016;374:1904-7. [Ref.ID 100324]
26.Enlace a cita original Cita con resumen
Laporte JR. Fifty years of pharmacovigilance - Medicines safety and public health. Pharmacoepidemiol Drug Saf 2016;25:725-32. [Ref.ID 99974]
28. Cita con resumen
Stafford N. German drug industry says pricing law is restricting access to some drugs. BMJ 2015;351:h6205. [Ref.ID 99692]
29. Cita con resumen
Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ 2015;351:h5542. [Ref.ID 99639]
30. Cita con resumen
Watson R. Council of Europe tackles drug industry’s “less noble” side. BMJ 2015;351:h5474. [Ref.ID 99593]
31. Cita con resumen
McCarthy M. Law makers question science behind US dietary guidelines. BMJ 2015;351:h5414. [Ref.ID 99592]
32. Cita con resumen
Allen K, Pearson-Stuttard J, Hooton W, Diggle P, Capewell S, O’Flaherty M. Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: cost effectiveness modelling study. BMJ 2015;351:h4583. [Ref.ID 99541]
33. Cita con resumen
Maynard A, Bloor K. Regulation of the pharmaceutical industry: promoting health or protecting wealth?. J R Soc Med 2015;108:220-2. [Ref.ID 99099]
34. Cita con resumen
Anónimo. Traité commercial États-Unis-Union européenee: menaces sur la santé. Prescrire 2015;35:218-9. [Ref.ID 98927]
35.Tiene citas relacionadas Cita con resumen
Köhler M, Haag S, Biester K, Brockhaus AC, McGauran N, Grouven U, Kölsch H, Seay U, Hörn H, Moritz G, Staeck K, Wieseler B. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports. BMJ 2015;350:h796. [Ref.ID 98850]
36.Tiene citas relacionadas Cita con resumen
Doshi P, Jefferson T. The evidence base for new drugs. BMJ 2015;350:h952. [Ref.ID 98849]
37. Cita con resumen
Watson R. Medicines to remain with European Commission Health Directorate. BMJ 2014;349:g6514. [Ref.ID 98359]
38. Cita con resumen
Midzuaray Midzuaray A. Uso racional de medicamentos. Panorama internacional. Revista Salud y Medicamentos 2014;17:21-9. [Ref.ID 98274]
39. Cita con resumen
Watson R. Critics attack transfer of responsibility for drugs in Europe. BMJ 2014;349:g5700. [Ref.ID 98051]
40. Cita con resumen
Martín Matas M. La factura farmacèutica. Ara 2014:42-3. [Ref.ID 97909]
Seleccionar todas
 
<< anterior 21 a 40 de 743 siguiente >>